Denmark
# |
Name |
Gross Profit Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
100.00%
|
Dec. 31, 2023 | USD 3.98 | 0.01% |
|
Denmark |
|
2 |
98.63%
|
Dec. 31, 2023 | USD 216.88 | 1.28% |
|
Denmark |
|
3 |
94.41%
|
Dec. 31, 2023 | USD 95.84 | 0.08% |
|
Denmark |
|
4 |
90.13%
|
June 30, 2024 | USD 70.50 | 0.61% |
|
Denmark |
|
5 |
84.60%
|
Dec. 31, 2023 | USD 81.56 | -2.90% |
|
Denmark |
|
6 |
83.36%
|
Dec. 31, 2023 | USD 131.57 | -1.84% |
|
Denmark |
|
7 |
83.08%
|
Dec. 31, 2023 | USD 1.93 | -6.19% |
|
Denmark |
|
8 |
77.48%
|
Dec. 31, 2023 | USD 5.46 | 0.56% |
|
Denmark |
|
9 |
69.96%
|
Dec. 31, 2023 | USD 0.57 | 1.47% |
|
Denmark |
|
10 |
65.19%
|
Dec. 31, 2023 | USD 0.20 | -2.77% |
|
Denmark |
|
11 |
65.03%
|
Dec. 31, 2023 | USD 0.85 | -3.38% |
|
Denmark |
|
12 |
64.69%
|
Sept. 30, 2024 | USD 109.06 | -0.12% |
|
Denmark |
|
13 |
64.10%
|
Dec. 31, 2023 | USD 26.62 | -0.36% |
|
Denmark |
|
14 |
62.91%
|
Dec. 31, 2023 | USD 20.15 | -0.78% |
|
Denmark |
|
15 |
56.06%
|
Dec. 31, 2023 | USD 91.43 | -1.85% |
|
Denmark |
|
16 |
54.92%
|
Sept. 30, 2024 | USD 18.73 | 1.26% |
|
Denmark |
|
17 |
54.32%
|
Dec. 31, 2023 | USD 54.16 | -1.39% |
|
Denmark |
|
18 |
48.27%
|
Dec. 31, 2023 | USD 2.17 | 5.88% |
|
Denmark |
The Pharmaceuticals company in Denmark with the highest Gross Profit Margin is FluoGuide A/S (Stockholm Stock Exchange: FLUO.ST) at 100.00%.
The Pharmaceuticals company in Denmark with the lowest Gross Profit Margin is ExpreS2ion Biotech Holding AB (publ) (Stockholm Stock Exchange: EXPRS2.ST) at 48.27%.
The top 10 Pharmaceuticals companies in Denmark by Gross Profit Margin are FluoGuide A/S, Genmab A/S, Zealand Pharma A/S, ChemoMetec A/S, Novo Nordisk A/S, Ascendis Pharma A/S, ViroGates A/S, H. Lundbeck A/S, Saniona AB (publ) and BioPorto A/S.
The bottom 10 Pharmaceuticals companies in Denmark by Gross Profit Margin are ExpreS2ion Biotech Holding AB (publ), Novozymes A/S, Ambu A/S, Gubra A/S, ALK-Abelló A/S, Bavarian Nordic A/S, Coloplast A/S, Q-Interline A/S, BioPorto A/S and Saniona AB (publ).